The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome
Abstract
In Brief Objective: Improved staging systems for malignant peripheral nerve sheath tumor (MPNST) prognostication and management are needed. Consequently, we sought to identify clinical, pathologic, and molecular predictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST. Methods: MPNST patients treated from 1986 to 2006 (n = 140) were identified; 72 had NF-1 syndrome and 68 did not. A comprehensive database was constructed. Paraffin-embedded neurofibroma or MPNST blocks were assembled in a tissue microarray; marker expression was evaluated immunohistochemically. Univariable and multivariable analyses identified independent factors prognostic of local recurrence, distant metastasis, and disease-specific survival (DSS). Results: DSS at 10 years was 31.6% for 87 primary disease patients, 25.9% for 26 recurrent patients, and 7.5% for 27 metastatic patients after median follow up of 91 months. The 5 years DSS for localized tumor patients was 35% for NF-1 patients and 50% for sporadic patients. MPNST ≥10 cm at diagnosis, partial resection, and metastasis development were significant negative predictors of DSS; completely resected tumors that lacked S-100 immunoreactivity had a nearly 5-fold increased risk of developing distant metastasis. Ki67, vascular endothelial growth factor, p53, and pMEK were over-expressed in MPNST compared with benign neurofibromas. Only tumor size and nuclear p53 expression were found to be independent prognosticators for MPNST DSS in a multivariable analysis. Conclusions: MPSNT is a markedly metastatic and aggressive poor prognosis tumor. Multiple clinical, pathologic, and molecular markers identified in this study, coupled with findings from previous series, should be considered for an improved MPNST staging system useful for prognostic assessment and management decisions. Clinical, pathologic, and molecular predictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST (n = 140) treated at a single institution were evaluated. Size ≥10 cm, partial resection, metastasis development, decreased S-100 and increased epidermal growth factor receptor and nuclear p53 expression levels were associated with significantly worse disease-specific MPNST survival in a univariable analysis. Tumor size and p53 expression levels remained independent in a multivariable analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases
Ducatman, B. S., Scheithauer, B. W., Piepgras, D. G., Reiman, H. M., & Ilstrup, D. M. (1986) · Cancer · doi:10.1002/1097-0142(19860515)57:10<2006::aid-cncr2820571022>3.0.co;2-6 · Cited by 1,581
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
Pisters, P. W., Leung, D. H., Woodruff, J., Shi, W., & Brennan, M. F. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1679 · Cited by 1,220
Cormier, J. N., & Pollock, R. E. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.94 · Cited by 835
Self-citationCoindre, J.-M., Terrier, P., Guillou, L., Le Doussal, V., Collin, F., Ranch�re, D., Sastre, X., Vilain, M.-O., Bonichon, F., & N'Guyen Bui, B. (2001) · Cancer · doi:10.1002/1097-0142(20010515)91:10<1914::aid-cncr1214>3.0.co;2-3 · Cited by 740
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., & Lowy, D. R. (1992) · Cell · doi:10.1016/0092-8674(92)90407-4 · Cited by 580 · cited 1×
“Despite the identification of the NF1 tumor suppressor gene and the characterization of its gene product neurofibromin as a potent negative regulator of oncogenic RAS signaling and contributor to MPNST pathogenesis, the molecular events involved in tumorigenesis of MPNST are still poorly understood.(32,33) Moreover, l…”
BackgroundHuson, S. M., Compston, D. A., Clark, P., & Harper, P. S. (1989) · Journal of Medical Genetics · doi:10.1136/jmg.26.11.704 · Cited by 540
Malignant peripheral nerve sheath tumor: analysis of treatment outcome
Wong, W. W., Hirose, T., Scheithauer, B. W., Schild, S. E., & Gunderson, L. L. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00223-5 · Cited by 458
Cited by
Malignant Peripheral Nerve Sheath Tumors
Farid, M., Demicco, E. G., Garcia, R., Ahn, L., Merola, P. R., Cioffi, A., & Maki, R. G. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0328 · Cited by 354
Schaefer, I.-M., Fletcher, C. D., & Hornick, J. L. (2016) · Modern Pathology · doi:10.1038/modpathol.2015.134 · Cited by 317
Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors
Zhang, M., Wang, Y., Jones, S., Sausen, M., McMahon, K., Sharma, R., Wang, Q., Belzberg, A. J., Chaichana, K., Gallia, G. L., et al. (2014) · Nature Genetics · doi:10.1038/ng.3116 · Cited by 301
Kolberg, M., Holand, M., Agesen, T. H., Brekke, H. R., Liestol, K., Hall, K. S., Mertens, F., Picci, P., Smeland, S., & Lothe, R. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos287 · Cited by 270
Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors
Bai, R.-Y., Esposito, D., Tam, A. J., McCormick, F., Riggins, G. J., Wade Clapp, D., & Staedtke, V. (2019) · Gene Therapy · doi:10.1038/s41434-019-0080-9 · Cited by 38
Metadata
- Authors
- Zou, C., Smith, K. D., Liu, J., Lahat, G., Myers, S., Wang, W.-L., Zhang, W., McCutcheon, I. E., Slopis, J. M., Lazar, A. J., Pollock, R. E., & Lev, D.
- Venue
- Annals of Surgery
- Published
- 2009-06
- Volume
- 249
- Issue
- 6
- Pages
- 1014-1022
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2031892485
- Cited by
- 313
- References
- 37
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.